



Form PTO-1449				Docket Number 377882001420		Application Number 09/927,422	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				Applicant Gary VAN NEST et al.			
				Filing Date August 10, 2001		Group Art Unit 1645	
				Mailing Date March 12, 2002			
U.S. PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date Appropriate
NMM	1.	07/03/1984	4,458,066	Caruthers et al.	—	—	
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
NMM	2.	09/20/2001	WO 01/68077 A2	WIPO			
NMM	3.	09/20/2001	WO 01/68103 A2	WIPO			
NMM	4.	09/20/2001	WO 01/68116 A2	WIPO			
NMM	5.	09/20/2001	WO 01/68143 A2	WIPO			
NMM	6.	09/20/2001	WO 01/68144 A2	WIPO			
NMM	7.	10/18/2001	WO 01/76642 A1	WIPO			
NMM	8.	09/20/2001	WO 01/68078 A2	WIPO			
NMM	9.	09/20/2001	WO 01/68117 A2	WIPO			
OTHER DOCUMENTS (including author, title, Date, Pertinent Pages, Etc.)							
Examiner Initials	Ref. No.	Title					
EXAMINER: /N. M. Minnifield/ (03/05/2007)				DATE CONSIDERED: 03/05/2007			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.							



Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/927,422
				Filing Date	August 10, 2001
				First Named Inventor	Gary VAN NEST
				Art Unit	1645
				Examiner Name	N. Minnifield
Sheet	1	of	2	Attorney Docket Number	377882001420


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
NMM	1.	US-2002/0055477-A1	05-09-2002	Nest et al.	
	2.	US-2003/0059773-A1	03-27-2003	Van Nest et al.	
	3.	US-5,629,158-A	05-13-1997	Uhlen	
	4.	US-5,770,434-A	06-23-1998	Huse	
	5.	US-5,824,812-A	10-20-1998	Nantz et al.	
	6.	US-6,352,975-B1	03-05-2002	Schreiner et al.	
	7.	US-6,355,267-B1	03-12-2002	Collins	
	8.	US-6,465,188-B1	10-15-2002	Gold et al.	
NMM	9.	US-6,559,129-B1	05-06-2003	Kasid et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² -Number ³ -Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear T ⁵
NMM	10.	WO-03/015816-A1	02-27-2003	Dynavax Technologies Corporation	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
NMM	11.	Agrawal, S. et al. (Febraury 2000). "Antisense Therapeutics: is it as Simple as Complementary Base Recognition?," <i>Molecular Med. Today</i> 6:72-81.			
NMM	12.	Busquets, M.A. et al. (November 2003). "Peptides and Liposomes: From Biophysical to Immunogenic Studies," <i>Current Drug Targets</i> 4(8):633-642.			
NMM	13.	Crooke, S.T. (1998). "Basic Principles of Antisense Therapeutics," Chapter 1 <i>In Antisense Research and Application</i> , Crooke, S.T. ed., Springer-Verlag: Berlin, Germany, pp. 1-50.			
NMM	14.	Du Bois, R.M. (October 21, 1999). "Interferon Gamma-1b for the Treatment of Idiopathic Pulmonary Fibrosis," <i>New England Journal of Medicine</i> 341(17):1302-1304.			
NMM	15.	Fearon, K. et al. (2003). "A Minimal Human Immunostimulatory CpG Motif That Potently Induces IFN- γ and IFN- α Production," <i>Eur. J. Immunol.</i> 33:2114-2122.			
NMM	16.	Fix, M. et al. (2002). "The Fluorosome™ Technique for Investigating Membrane On- and Off-Loading of Drugs by β -CD and Sonicated SUV," <i>FEBS Letters</i> 516:109-112.			
NMM	17.	International Search Report mailed on February 11, 2002 for PCT Application No. PCT/US01/07848 filed March 12, 2001, three pages.			
NMM	18.	International Search Report mailed on August 27, 2002 for PCT Application No. PCT/US01/25364 filed August 13, 2001, four pages.			
NMM	19.	International Search Report mailed on February 11, 2002 for PCT Application No. PCT/US01/07843 filed March 12, 2001, three pages.			
NMM	20.	Li, Q.T. et al. (1993). "Effect of Cholesteryl Ester on the Distribution of Fluorescent Cholesterol Analogues in Triacylglycerol-rich Emulsions," <i>Biochimica et Biophysica Acta</i> 1166(2/3):145-			

Examiner Signature	/N. M. Minnifield/ (01/12/2007)	Date Considered	01/12/2007
--------------------	---------------------------------	-----------------	------------



Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/927,422
		Filing Date	August 10, 2001
		First Named Inventor	Gary VAN NEST
		Art Unit	1645
		Examiner Name	N. Minnifield
Sheet	2	of	2
		Attorney Docket Number	377882001420

		153.	
NMM	21.	Peracchi, A. (2004). "Prospects for Antiviral Ribozymes and Deoxyribozymes," <i>Rev. Med. Virol.</i> 14:47-64.	
NMM	22.	Stayton, P.S. et al. (2000). "Molecular Engineering of Proteins and Polymers for Targeting and Intracellular Delivery of Therapeutics," <i>J. Controlled Release</i> 65:203-220.	
NMM	23.	Van Uden, J. et al. (November 1999). "Immunostimulatory DNA and Applications to Allergic Disease," <i>Journal of Allergy and Clinical Immunology</i> 104(5):902-910.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/N. M. Minnifield/ (01/12/2007)	Date Considered	01/12/2007
--------------------	---------------------------------	-----------------	------------

pa-1058859

NOV 27 2001

TECH CENTER 1600/2900

PTO/SB/08 (2-92)
Sheet 1 of 12

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 377882001420

Application Number 09/927,422

Applicant

Gary VAN NEST et al.

Filing Date August 10, 2001

Group Art Unit ~~1645~~

Mailing Date November 13, 2001

RECEIVED

NOV 27 2001

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
NMM	1.	07/03/1984	4,458,006	Döenges et al.			
	2.	03/17/1987	4,650,675	Borel et al.			
	3.	07/18/1989	4,849,513	Smith et al.			
	4.	03/20/1990	4,910,300	Urdea et al.			
	5.	08/14/1990	4,948,882	Ruth			
	6.	05/14/1991	5,015,733	Smith et al.			
	7.	03/03/1992	5,093,232	Urdea et al.			
	8.	06/02/1992	5,118,800	Smith et al.			
	9.	06/02/1992	5,118,802	Smith et al.			
	10.	06/23/1992	5,124,246	Urdea et al.			
	11.	02/21/1995	5,391,723	Priest			
	12.	09/26/1995	5,453,496	Caruthers et al.			
	13.	01/16/1996	5,484,596	Hanna, Jr. et al.			
	14.	09/02/1997	5,663,153	Hutcherson et al.			
	15.	03/03/1998	5,723,335	Hutcherson et al.			
	16.	12/15/1998	5,849,719	Carson et al.			
	17.	01/16/2001	6,174,872	Carson et al.			
	18.	02/27/2001	6,194,388 B1	Krieg et al.			
	19.	03/27/2001	6,207,646 B1	Krieg et al.			
V	20.	04/10/2001	6,214,806 B1	Krieg et al.			
NMM	21.	05/29/2001	6,239,116 B1	Krieg et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
NMM	22.	01/29/1992	0 468 520 A2,A3	Europe			

EXAMINER: /N. M. Minnifield/ (03/05/2007)

DATE CONSIDERED: 03/05/2007

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 377882001420

Application Number 09/927,422

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

Applicant

Gary VAN NEST et al.

Filing Date August 10, 2001

Group Art Unit **1645**

Mailing Date November 13, 2001

(Use several sheets if necessary)

23.	02/01/1996	WO 96/02555 A1	WIPO				
24.	08/07/1997	WO 97/28259 A1	WIPO				
25.	04/23/1998	WO 98/16247 A1	WIPO				
26.	05/07/1998	WO 98/18810 A1	WIPO				
27.	09/03/1998	WO 98/37919 A1	WIPO				
28.	09/17/1998	WO 98/40100 A1	WIPO				
29.	11/26/1998	WO 98/52581 A1	WIPO				
30.	11/26/1998	WO 98/52962 A1	WIPO				
31.	12/10/1998	WO 98/55495 A2,A3	WIPO				
32.	12/10/1998	WO 98/55609 A1	WIPO				
33.	03/11/1999	WO 99/11275 A2,A3	WIPO				
34.	07/08/1999	WO 99/33488 A2,A3	WIPO				
35.	07/08/1999	WO 99/33868 A2,A3	WIPO				
36.	10/14/1999	WO 99/51259 A2,A3	WIPO				
37.	11/11/1999	WO 99/56755 A1	WIPO				
38.	12/09/1999	WO 99/62923 A2,A3	WIPO				
39.	02/10/2000	WO 00/06588 A1	WIPO				
40.	03/30/2000	WO 00/16804 A1	WIPO				
41.	04/20/2000	WO 00/21556 A1	WIPO				
42.	09/21/2000	WO 00/54803 A2	WIPO				
43.	10/19/2000	WO 00/61161 A2	WIPO				
44.	11/09/2000	WO 00/67023 A1	WIPO				
45.	02/22/2001	WO 01/12223 A2	WIPO				
46.	03/08/2001	WO 01/15726 A2	WIPO				
47.	04/05/2001	WO 01/22972 A2	WIPO				
48.	04/05/2001	WO 01/22990 A2	WIPO				
49.	05/25/2001	WO 01/35991 A2	WIPO				
50.	07/19/2001	WO 01/51500 A1	WIPO				
51.	08/02/2001	WO 01/54720 A1	WIPO				

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

EXAMINER: /N. M. Minnifield/ (03/05/2007)

DATE CONSIDERED: 03/05/2007

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO 1449		Docket Number 377882001420	Application Number 09/927,422																																													
INFORMATION DISCLOSURE CITATION IN AN APPLICATION NOV 26 2001 (Use several sheets if necessary)		Applicant Gary VAN NEST et al.																																														
		Filing Date August 10, 2001	Group Art Unit 1645																																													
		Mailing Date November 13, 2001																																														
<table border="1"> <thead> <tr> <th>Examiner Initials</th> <th>Ref. No.</th> <th>Title</th> </tr> </thead> <tbody> <tr> <td>NMM</td> <td>52.</td> <td>Asanuma, H. et al., (1995) "Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration" <i>Vaccine</i> 13:3-5.</td> </tr> <tr> <td></td> <td>53.</td> <td>Agrawal et al. (1986). "Efficient methods for attaching non-radioactive labels to the 5' ends of synthetic oligodeoxyribonucleotides," <i>Nucleic Acids Res.</i> 14:6227-6245.</td> </tr> <tr> <td></td> <td>54.</td> <td>Ahmeida, E.T.S. Ben, (1993). "Immunopotential of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice," <i>Vaccine</i> 11(13):1302-1309.</td> </tr> <tr> <td></td> <td>55.</td> <td>Atherton et al. (1981). "Synthesis of a 21-residue fragment of human proinsulin by the polyamide solid phase method," <i>Hoppe-Seylers Z. Physiol. Chem.</i> 362:833-839.</td> </tr> <tr> <td></td> <td>56.</td> <td>Ballas et al. (1996). "Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA," <i>J. Immunol.</i> 157:1840-1845.</td> </tr> <tr> <td></td> <td>57.</td> <td>Benoit et al. (1987). "Peptides. Strategies for antibody production and radioimmunoassays," <i>Neuromethods</i> 6:43-72.</td> </tr> <tr> <td></td> <td>58.</td> <td>Bischoff et al. (1987). "Introduction of 5'-terminal functional groups into synthetic oligonucleotides for selective immobilization," <i>Analytical Biochemistry</i> 164:336-344.</td> </tr> <tr> <td></td> <td>59.</td> <td>Blanks et al. (1988). "An oligodeoxynucleotide affinity column for the isolation of sequence specific DNA binding proteins," <i>Nucleic Acids Res.</i> 16:10283-10299.</td> </tr> <tr> <td></td> <td>60.</td> <td>Boujrad et al. (1993). "Inhibition of hormone-stimulated steroidogenesis in cultured Leydig tumor cells by a cholesterol-linked phosphorothioate oligodeoxynucleotide antisense to diazepam-binding inhibitor," <i>Proc. Natl. Acad. Sci. USA</i> 90:5728-5731.</td> </tr> <tr> <td></td> <td>61.</td> <td>Branda et al. (1993). "Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1," <i>Biochem. Pharmacol.</i> 45:2037-2043.</td> </tr> <tr> <td></td> <td>62.</td> <td>Branda et al. (1996). "Amplification of antibody production by phosphorothioate oligodeoxynucleotides," <i>J. Lab. Clin. Med.</i> 128:329-338.</td> </tr> <tr> <td></td> <td>63.</td> <td>Braun et al. (1988). "Immunogenic duplex nucleic acids are nuclease resistant," <i>J. Immunol.</i> 141:2084-2089.</td> </tr> <tr> <td></td> <td>64.</td> <td>Brazolot Millan et al. (1998) "CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice," <i>Proc. Natl. Acad. Sci. USA</i> 95:15553-15558.</td> </tr> <tr> <td>NMM</td> <td>65.</td> <td>Breiteneder et al. (1989). "The gene coding for the major birch pollen allergen <i>Betv1</i> is highly homologous to a pea disease resistance response gene," <i>EMBO J.</i> 8:1935-1938.</td> </tr> </tbody> </table>				Examiner Initials	Ref. No.	Title	NMM	52.	Asanuma, H. et al., (1995) "Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration" <i>Vaccine</i> 13:3-5.		53.	Agrawal et al. (1986). "Efficient methods for attaching non-radioactive labels to the 5' ends of synthetic oligodeoxyribonucleotides," <i>Nucleic Acids Res.</i> 14:6227-6245.		54.	Ahmeida, E.T.S. Ben, (1993). "Immunopotential of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice," <i>Vaccine</i> 11(13):1302-1309.		55.	Atherton et al. (1981). "Synthesis of a 21-residue fragment of human proinsulin by the polyamide solid phase method," <i>Hoppe-Seylers Z. Physiol. Chem.</i> 362:833-839.		56.	Ballas et al. (1996). "Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA," <i>J. Immunol.</i> 157:1840-1845.		57.	Benoit et al. (1987). "Peptides. Strategies for antibody production and radioimmunoassays," <i>Neuromethods</i> 6:43-72.		58.	Bischoff et al. (1987). "Introduction of 5'-terminal functional groups into synthetic oligonucleotides for selective immobilization," <i>Analytical Biochemistry</i> 164:336-344.		59.	Blanks et al. (1988). "An oligodeoxynucleotide affinity column for the isolation of sequence specific DNA binding proteins," <i>Nucleic Acids Res.</i> 16:10283-10299.		60.	Boujrad et al. (1993). "Inhibition of hormone-stimulated steroidogenesis in cultured Leydig tumor cells by a cholesterol-linked phosphorothioate oligodeoxynucleotide antisense to diazepam-binding inhibitor," <i>Proc. Natl. Acad. Sci. USA</i> 90:5728-5731.		61.	Branda et al. (1993). "Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1," <i>Biochem. Pharmacol.</i> 45:2037-2043.		62.	Branda et al. (1996). "Amplification of antibody production by phosphorothioate oligodeoxynucleotides," <i>J. Lab. Clin. Med.</i> 128:329-338.		63.	Braun et al. (1988). "Immunogenic duplex nucleic acids are nuclease resistant," <i>J. Immunol.</i> 141:2084-2089.		64.	Brazolot Millan et al. (1998) "CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice," <i>Proc. Natl. Acad. Sci. USA</i> 95:15553-15558.	NMM	65.	Breiteneder et al. (1989). "The gene coding for the major birch pollen allergen <i>Betv1</i> is highly homologous to a pea disease resistance response gene," <i>EMBO J.</i> 8:1935-1938.
Examiner Initials	Ref. No.	Title																																														
NMM	52.	Asanuma, H. et al., (1995) "Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration" <i>Vaccine</i> 13:3-5.																																														
	53.	Agrawal et al. (1986). "Efficient methods for attaching non-radioactive labels to the 5' ends of synthetic oligodeoxyribonucleotides," <i>Nucleic Acids Res.</i> 14:6227-6245.																																														
	54.	Ahmeida, E.T.S. Ben, (1993). "Immunopotential of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice," <i>Vaccine</i> 11(13):1302-1309.																																														
	55.	Atherton et al. (1981). "Synthesis of a 21-residue fragment of human proinsulin by the polyamide solid phase method," <i>Hoppe-Seylers Z. Physiol. Chem.</i> 362:833-839.																																														
	56.	Ballas et al. (1996). "Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA," <i>J. Immunol.</i> 157:1840-1845.																																														
	57.	Benoit et al. (1987). "Peptides. Strategies for antibody production and radioimmunoassays," <i>Neuromethods</i> 6:43-72.																																														
	58.	Bischoff et al. (1987). "Introduction of 5'-terminal functional groups into synthetic oligonucleotides for selective immobilization," <i>Analytical Biochemistry</i> 164:336-344.																																														
	59.	Blanks et al. (1988). "An oligodeoxynucleotide affinity column for the isolation of sequence specific DNA binding proteins," <i>Nucleic Acids Res.</i> 16:10283-10299.																																														
	60.	Boujrad et al. (1993). "Inhibition of hormone-stimulated steroidogenesis in cultured Leydig tumor cells by a cholesterol-linked phosphorothioate oligodeoxynucleotide antisense to diazepam-binding inhibitor," <i>Proc. Natl. Acad. Sci. USA</i> 90:5728-5731.																																														
	61.	Branda et al. (1993). "Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1," <i>Biochem. Pharmacol.</i> 45:2037-2043.																																														
	62.	Branda et al. (1996). "Amplification of antibody production by phosphorothioate oligodeoxynucleotides," <i>J. Lab. Clin. Med.</i> 128:329-338.																																														
	63.	Braun et al. (1988). "Immunogenic duplex nucleic acids are nuclease resistant," <i>J. Immunol.</i> 141:2084-2089.																																														
	64.	Brazolot Millan et al. (1998) "CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice," <i>Proc. Natl. Acad. Sci. USA</i> 95:15553-15558.																																														
NMM	65.	Breiteneder et al. (1989). "The gene coding for the major birch pollen allergen <i>Betv1</i> is highly homologous to a pea disease resistance response gene," <i>EMBO J.</i> 8:1935-1938.																																														
EXAMINER: /N. M. Minnifield/ (03/05/2007)		DATE CONSIDERED: 03/05/2007																																														
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.																																																

Form PTO-1449		Docket Number 377882001420	Application Number 09/927,422
INFORMATION DISCLOSURE CITATION IN AN APPLICATION NOV 26 2001 PATENT & TRADEMARK OFFICE (Use several sheets if necessary)		Applicant Gary VAN NEST et al.	
		Filing Date August 10, 2001	Group Art Unit 1645
		Mailing Date November 13, 2001	
NMM	66.	Broide et al. (1998). "Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice," <i>J. Immunol.</i> 161:7054-7062.	
	67.	Broide et al. (1999). "DNA-based immunization for asthma," <i>Int. Arch. Allergy Immunol.</i> 118:453-456.	
	68.	Carson et al. (1997). "Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination," <i>J. Exp. Med.</i> 186:1621-1622.	
	69.	Chace et al. (1997). "Bacterial DNA-induced NK cell IFN- γ production is dependent on macrophage secretion of IL-12," <i>Clin. Immunol. and Immunopathol.</i> 84:185-193.	
	70.	Chaturvedi et al. (1996). "Stabilization of triple-stranded oligonucleotide complexes: use of probes containing alternating phosphodiester and stereo-uniform cationic phosphoramidate linkages," <i>Nucleic Acids Res.</i> 24:2318-2323.	
	71.	Chen et al. (1999). "Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs," <i>Vaccine</i> 17:653-659.	
	72.	Chu et al. (1997). "CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity," <i>J. Exp. Med.</i> 186:1623-1631.	
	73.	Chua et al. (1988). "Sequence analysis of cDNA coding for a major house dust mite allergen, <i>Der p 1</i> homology with cysteine proteases," <i>J. Exp. Med.</i> 167:175-182.	
	74.	Chua et al. (1990). "Expression of <i>Dermatophagoides pteronyssinus</i> allergen, <i>Der p II</i> , in <i>Escherichia coli</i> and the binding studies with human IgE," <i>Int. Arch. Allergy Appl. Immunol.</i> 91:124-129.	
	75.	Connolly, Bernard A. (1985). "Chemical synthesis of oligonucleotides containing a free sulphhydryl group and subsequent attachment of thiol specific probes," <i>Nucleic Acids Res.</i> 13:4485-4502.	
	76.	Connolly, Bernard A. (1987). "The synthesis of oligonucleotides containing a primary amino group at the 5'-terminus," <i>Nucleic Acids Res.</i> 15:3131-3139.	
	77.	Corey et al. (1987). "Generation of a hybrid sequence-specific single-stranded deoxyribonuclease," <i>Science</i> 238:1401-1403.	
	78.	Cowdery et al. (1996). "Bacterial DNA induces NK cells to produce IFN- γ <i>in vivo</i> and increases the toxicity of lipopolysaccharides," <i>J. Immunol.</i> 156:4570-4575.	
	79.	de Martino et al. (1999). "Low IgG3 and high IgG4 subclass levels in children with advanced human immunodeficiency virus-type 1 infection and elevated IgE levels," <i>Ann. Allergy Asthma Immunol.</i> 83:160-164.	
NMM	80.	Elkins et al., (1999) "Bacterial DNA comprising CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria" <i>J. Immunol.</i> 162:2291-2298.	
EXAMINER: /N. M. Minnifield/ (03/05/2007)		DATE CONSIDERED: 03/05/2007	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449		Docket Number 377882001420	Application Number 09/927,422
INFORMATION DISCLOSURE CITATION IN AN APPLICATION NOV 26 2001 Use several sheets if necessary)		Applicant Gary VAN NEST et al.	
		Filing Date August 10, 2001	Group Art Unit 102 1645
		Mailing Date November 13, 2001	
NMM	81.	Elsayed et al. (1991). "The structural requirements of epitopes with IgE binding capacity demonstrated by three major allergens from fish, egg and tree pollen," <i>Scand. J. Clin. Lab. Invest.</i> 51(Suppl.204):17-31.	
	82.	Fornadley, John (1998). "Allergy immunotherapy," <i>Otolaryngol. Clin. North Am.</i> 31:111-127.	
	83.	Gao et al., (1995). "Circularization of oligonucleotides by disulfide bridge formation," <i>Nucleic Acids Res.</i> 23(11):2025-2029.	
	84.	Geoghegan et al. (1992). "Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine," <i>Bioconjug. Chem.</i> 3:138-146.	
	85.	Godard et al. (1995) "Antisense effects of cholesterol-oligodeoxynucleotide conjugates associated with poly(alkylcyanoacrylate) nanoparticles" <i>Eur. J. Biochem.</i> 232:404-410.	
	86.	Goodchild, John (1990). "Conjugates of oligonucleotides and modified oligonucleotides: A review of their synthesis and properties" <i>Bioconjug. Chem.</i> 1(3):165-187.	
	87.	Govorkova and Smirnov (1997). "Cross-protection of mice immunized with different influenza A (H2) strains and challenged with viruses of the same HA subtype," <i>Acta Virol.</i> 41:251-257.	
	88.	Grabarek et al., "Zero-length crosslinking procedure with the use of active esters" (1990) <i>Anal. Biochem.</i> 185:131-135	
	89.	Gramzinski et al., "Immune response to a hepatitis B DNA vaccine in aotus monkeys: A comparison of vaccine formulation, route, and method of administration" (1998) <i>Mol. Med.</i> 4:109-118	
	90.	Granoff, Dan M. (1993). "Effect of immunity to the carrier protein on antibody responses to <i>Haemophilus influenzae</i> type b conjugate vaccines," <i>Vaccine</i> 11(1):S46-S51.	
	91.	Haralambidis et al. (1990). "The synthesis of polyamide-oligonucleotide conjugate molecules," <i>Nucleic Acids Res.</i> 18:493-499.	
	92.	Haralambidis et al. (1990). "The preparation of polyamide-oligonucleotide probes containing multiple non-radioactive labels," <i>Nucleic Acids Res.</i> 18:501-505.	
	93.	Horner et al. (1998). "Rapid communication: Immunostimulatory DNA is a potent mucosal adjuvant," <i>Cell Immunol.</i> 190:77-82.	
	94.	Jäger et al. (1988). "Oligonucleotide N-alkylphosphoramidates: Synthesis and binding to polynucleotides," <i>Biochem.</i> 27:7237-7246.	
NMM	95.	Jakob et al. (1998). "Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA," <i>J. Immunol.</i> 161:3042-3049.	
EXAMINER: /N. M. Minnifield/ (03/05/2007)			
EXAMINER:		DATE CONSIDERED: 03/05/2007	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449

Docket Number 377882001420

Application Number 09/927,422

INFORMATION DISCLOSURE CITATION
BY AN APPLICATION

Applicant

Gary VAN NEST et al.

NOV 26 2001

(Use several sheets if necessary)

Filing Date August 10, 2001

Group Art Unit ~~1645~~

Mailing Date November 13, 2001

NMM

- | | |
|------|--|
| 96. | Kandimalla, E.R. et al., (2001) "Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships" <i>Bioorg. Med. Chem.</i> 9:807-813. |
| 97. | Kataoka et al. (1992). "Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of <i>mycobacterium bovis</i> BCG," <i>Jpn. J. Cancer Res.</i> 83:244-247. |
| 98. | Kikuta, K. et al., (1990) "Cross-protection against influenza B type virus infection by intranasal inoculation of the HA vaccines combined with cholera toxin B subunit <i>Vaccine</i> 8:595-599 |
| 99. | Kimura et al. (1994). "Binding of oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN," <i>J. Biochem. (Tokyo)</i> 116:991-994. |
| 100. | Kline et al. (1997). "Immune redirection by CpG oligonucleotides conversion of a Th2 response to a Th1 response in a murine model of asthma," <i>J. Invest. Med.</i> 45(3):282A. |
| 101. | Klinman et al. (1996). "CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ ," <i>Proc. Natl. Acad. Sci. USA</i> 93:2879-2883. |
| 102. | Klinman et al., (1997). "Contribution of CpG motifs to the immunogenicity of DNA vaccines," <i>J. Immunol.</i> 158:3635-3639. |
| 103. | Kodihalli et al., (1997). "Cross-protection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin," <i>J. Virol.</i> 71(5):3391-3396. |
| 104. | Kovarik et al. (1999). "CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming," <i>J. Immunol.</i> 162:1611-1617. |
| 105. | Kremsky et al. (1987). "Immobilization of DNA via oligonucleotides containing an aldehyde or carboxylic acid group at the 5' terminus," <i>Nucleic Acids Res.</i> 15:2891-2909. |
| 106. | Krieg, Arthur M. (1996). "Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA," <i>Trends in Microbiology</i> 4:73-77. |
| 107. | Krieg, Arthur M. (1998). "Leukocyte stimulation by oligodeoxynucleotides" Chapter 24 in <i>Applied Antisense Oligonucleotide Technology</i> . C.A. Stein et al. eds. Wiley-Liss, Inc.: pp. 431-448. |
| 108. | Krieg et al. (1989). "A role for endogenous retroviral sequences in the regulation of lymphocyte activation," <i>J. Immunol.</i> 143:2448-2451. |
| 109. | Krieg et al. (1995). "CpG motifs in bacterial DNA trigger direct B-cell activation" <i>Nature</i> 374:546-549. |
| 110. | Krieg et al. (1996). "Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs," <i>Antisense & Nucleic Acid Drug Dev.</i> 6:133-139. |

EXAMINER: /N. M. Minnifield/ (03/05/2007)

DATE CONSIDERED: 03/05/2007

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 <div style="text-align: center;"> INFORMATION DISCLOSURE CITATION IN AN APPLICATION NOV 26 2001 (Use several sheets if necessary) </div>		Docket Number 377882001420	Application Number 09/927,422
Applicant <div style="text-align: center;">Gary VAN NEST et al.</div>		Filing Date August 10, 2001	
Mailing Date November 13, 2001		Group Art Unit 1645	

NMM	Citation Number	Citation
	111.	Krieg et al., (1998). "The role of CpG dinucleotides in DNA vaccines" <i>Trends Microbiol.</i> 6:23-27
	112.	Krieg et al., "CpG DNA induces sustained IL-12 expression in vivo and resistance to <i>listeria monocytogenes</i> challenge" (1998) <i>J. Immunol.</i> 161:2428-2434
	113.	Krieg et al., "Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs" (1998) <i>Proc. Natl. Acad. Sci. USA</i> 95:12631-12636
	114.	Krieg et al., (1999) "CpG DNA: a novel immunomodulator" <i>Trends Microbiol.</i> 7(2):64-65.
	115.	Latimer et al., "Specificity of monoclonal antibodies produced against phosphorothioate and ribo modified DNAs" (1995) <i>Mol. Immunol.</i> 32:1057-1064
	116.	Lea et al., "Cloning and sequencing of cDNAs encoding the human sperm protein, Sp17" (1996) <i>Biochim. Biophys. Acta</i> 1307:263-266
	117.	Leclerc et al., (1997) "The preferential induction of a TH1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA" <i>Cell. Immunol.</i> 179:97-106.
	118.	Liang, Hua et al. (1996). "Activation of human B cells by phosphorothioate oligodeoxynucleotides," <i>J. Clin. Invest.</i> 98(5):1119-1129.
	119.	Lipford et al., "Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines" (1997) <i>Eur. J. Immunol.</i> 27:3420-3426.
	120.	Lipford et al., "CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants" (1997) <i>Eur. J. Immunol.</i> 27:2340-2344
	121.	Liu et al., "Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor" (1998) <i>Blood</i> 92:3730-3736
	122.	Macfarlane et al., "Unmethylated CpG-containing oligodeoxynucleotides inhibit apoptosis in WEHI 231 B lymphocytes induced by several agents: evidence for blockade of apoptosis at a distal signalling step" (1997) <i>Immunology</i> 91:586-593
	123.	Malley, Arthur, "The immune response of offspring mice from mothers immunized during pregnancy with protein antigens" (1989) <i>J. Reprod. Immunol.</i> 16:173-186
	124.	Manzel et al., (1999) "Lack of immune stimulation by immobilized CpG-oligodeoxynucleotide" <i>Antisense Nucl. Acid Drug Dev.</i> 9:459-464.
	125.	Martin-Orozco et al., "Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences" (1999) <i>Intnl Immunol.</i> 11(7):1111-1118
↓ NMM	126.	Mbawuike et al., "Influenza: A subtype cross-protection after immunization of outbred mice with a purified chimeric NS ₁ /HA ₂ influenza virus protein" (1994) <i>Vaccine</i> 12(14):1340-1348

EXAMINER: /N. M. Minnifield/ (03/05/2007)	DATE CONSIDERED: 03/05/2007
---	-----------------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 377882001420	Application Number 09/927,422
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Gary VAN NEST et al.	
		Filing Date August 10, 2001	Group Art Unit 164 1645
		Mailing Date November 13, 2001	
NMM	143.	Raz et al., "Preferential induction of a Th ₁ immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization" (1996) <i>Proc. Natl. Acad. Sci. USA</i> 93:5141-5145	
	144.	Redford et al., "Cyclosporin A enhances IL-12 production by CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides" (1998) <i>J. Immunol.</i> 161:3930-3935	
	145.	Rogers et al., "Recombinant <i>Fel d</i> I: Expression, purification, IgE binding and reaction with cat-allergic human T cells" (1993) <i>Mol. Immunol.</i> 30:559-568	
	146.	Roget et al., "Synthesis and use of labelled nucleoside phosphoramidite building blocks bearing a reporter group: biotinyl, dinitrophenyl, pyrenyl and dansyl" (1989) <i>Nucleic Acids Res.</i> 17:7643-7651	
	147.	Romagnani, S. (2000) "T-cell subsets (Th1 versus Th2) <i>Ann. Allergy Asthma Immunol.</i> 85:9-18.	
	148.	Roman et al., "Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants" (1997) <i>Nature Medicine</i> 3:849-854	
	149.	Ruth, Jerry L., "Oligodeoxynucleotides with reporter groups attached to the base" (1991) <i>Oligonucleotides and Analogues: A Practical Approach</i> , Eckstein, ed., IRL Press, pp. 255-282	
	150.	Sato et al., "Immunostimulatory DNA sequences necessary for effective intradermal gene immunization" (1996) <i>Science</i> 273:352-354	
	151.	Schacht et al., (1996) "Biomedical applications of degradable polyphosphazenes" <i>Biotechnol. Bioeng.</i> 52:102-108.	
	152.	Scherle et al., "Functional analysis of influenza specific helper T cell clones <i>in vivo</i> " (1986) <i>J. Exp. Med.</i> 164:1114-1128	
	153.	Scherle et al., "Differential ability of B cells specific for external vs. internal influenza virus proteins to respond to help from influenza virus-specific T-cell clones <i>in vivo</i> " (1988) <i>Proc. Natl. Acad. Sci. USA</i> 85:4446-4450	
	154.	Schultz et al., "Oligo-2'-fluoro-2'-deoxynucleotide N3'→P5' phosphoramidates: synthesis and properties" (1996) <i>Nucleic Acids Res.</i> 24:2966-2973	
	155.	Schwartz et al., "CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract" (1997) <i>J. Clin. Invest.</i> 100:68-73	
	156.	Shimada et al., "In vivo augmentation of natural killer cell activity with a deoxyribonucleic acid fraction of BCG" (1986) <i>Jpn. J. Cancer Res.</i> 77:808-816	
NMM	157.	Sinha et al., "Oligonucleotides with reporter groups attached to the 5'-terminus" (1991) <i>Oligonucleotide Analogues: A Practical Approach</i> , Eckstein, ed., IRL Press, pp. 185-210	
EXAMINER: /N. M. Minnifield/ (03/05/2007) DATE CONSIDERED: 03/05/2007			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449		Docket Number 377882001420	Application Number 09/927,422
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Gary VAN NEST et al.	
		Filing Date August 10, 2001	Group Art Unit 1645 1645
		Mailing Date November 13, 2001	
NMM	158.	Sonehara et al., "Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon" (1996) <i>J. Interferon and Cytokine Res.</i> 16:799-803	
	159.	Sparwasser et al., "Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor- α -mediated shock" (1997) <i>Eur. J. Immunol.</i> 27:1671-1679	
	160.	Spiegelberg et al., "Inhibition of IgE formation and allergic inflammation by allergen gene immunization and by CpG motif immunostimulatory oligodeoxynucleotides" (1998) <i>Allergy</i> 53:93-97	
	161.	Spiegelberg et al., "Inhibition of allergic inflammation in the lung by plasmid DNA allergen immunization" (1999) <i>Pediatric Pulmonology Suppl.</i> 18:118-121	
	162.	Stacey et al., "Macrophages ingest and are activated by bacterial DNA" (1996) <i>J. Immunol.</i> 157:2116-2122	
	163.	Staros et al., "Enhancement by <i>N</i> -hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions" (1986) <i>Anal. Biochem.</i> 156:220-222.	
	164.	Stein et al., "Chapter 11: Non-antisense effects of oligodeoxynucleotides" (1997) <i>Antisense Technology</i> , C. Lichtenstein and W. Nellen, eds., IRL Press, pp. 241-264.	
	165.	Stirchak et al., "Uncharged stereoregular nucleic acid analogs: 2. Morpholino nucleoside oligomers with carbamate internucleoside linkages" (1989) <i>Nucleic Acids Res.</i> 17:6129-6141	
	166.	Tamura et al., "Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine" (1992) <i>Eur. J. Immunol.</i> 22:477-481	
	167.	Tamura et al., "Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice" (1994) <i>Vaccine</i> 12:310-316	
	168.	Tokunaga et al., "Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of <i>Mycobacterium bovis</i> BCG induce interferons and activate natural killer cells" (1992) <i>Microbiol. Immunol.</i> 36:55-66	
	169.	Tung et al., "Preparation of oligonucleotide-peptide conjugates" (1991) <i>Bioconjug. Chem.</i> 2:464-465	
	170.	Verhelvi, D. et al., (February 15, 2001) "Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs" <i>J. Immunol.</i> 166(4):2372-2377.	
	171.	Wang et al., "Circular RNA oligonucleotides. Synthesis, nucleic acid binding properties, and a comparison with circular DNAs" (1994) <i>Nucleic Acids Res.</i> 22:2326-2333	
	172.	Warner et al., "Laboratory methods. Construction and evaluation of an instrument for the automated synthesis of oligodeoxyribonucleotides" (1984) <i>DNA</i> 3:401-411	
NMM	173.	Weeratna et al. (1998) "Brief Communication: Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides" <i>Antisense & Nucleic Acid Drug Development</i> 8:351-356.	
EXAMINER: /N. M. Minnifield/ (03/05/2007) DATE CONSIDERED: 03/05/2007			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449 <div style="border: 1px solid black; border-radius: 50%; width: 100px; height: 100px; display: flex; align-items: center; justify-content: center; margin: 10px auto;"> <div style="text-align: center;"> <p>INFORMATION DISCLOSURE CITATION ON AN APPLICATION</p> <p>NOV 26 2001</p> <p>PATENT & TRADEMARK OFFICE</p> </div> </div> <p>(Use several sheets if necessary)</p>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Docket Number 377882001420</td> <td style="width: 50%;">Application Number 09/927,422</td> </tr> <tr> <td colspan="2">Applicant Gary VAN NEST et al.</td> </tr> <tr> <td>Filing Date August 10, 2001</td> <td>Group Art Unit 2002 1645</td> </tr> <tr> <td colspan="2">Mailing Date November 13, 2001</td> </tr> </table>		Docket Number 377882001420	Application Number 09/927,422	Applicant Gary VAN NEST et al.		Filing Date August 10, 2001	Group Art Unit 2002 1645	Mailing Date November 13, 2001	
Docket Number 377882001420	Application Number 09/927,422										
Applicant Gary VAN NEST et al.											
Filing Date August 10, 2001	Group Art Unit 2002 1645										
Mailing Date November 13, 2001											
NMM	174.	Weiner et al., "Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization" (1997) <i>Proc. Natl. Acad. Sci. USA</i> 94:10833-10837									
175.	Widhe, M. et al. (1998). "IgG subclasses in lyme borreliosis: A study of specific IgG subclass distribution in an interferon- γ -predominated disease," <i>Scand. J. Immunol.</i> 47:575-581.										
176.	Wooldridge et al., "Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma" (1997) <i>Blood</i> 89:2994-2998										
177.	Yamamoto et al., "Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment INF-mediated natural killer activity" (1992) <i>J. Immunol.</i> 148:4072-4076										
178.	Yamamoto et al. (1994) "Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length" <i>Antisense Research and Development</i> 4:119-122.										
179.	Yamamoto et al., "Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes <i>in vitro</i> " (1994) <i>Jpn. J. Cancer Res.</i> 85:775-779										
180.	Yanagawa et al., "Analysis of superhelical structures of nucleic acid-lipid conjugates by image processing" (1988) <i>Nucleic Acids Symp. Series</i> 19:189-192.										
181.	Yi et al. (1996) "IFN- γ promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligonucleotides" <i>J. Immunol.</i> 156:558-564										
182.	Yi et al., "CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of I κ B α and I κ B β and sustained activation of nuclear factor- κ B/c-Rel" (1998) <i>J. Immunol.</i> 160:1240-1245										
183.	Yi et al., "CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species" (1998) <i>J. Immunol.</i> 160:4755-4761										
184.	Yi et al., "CpG oligodeoxynucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry" (1998) <i>J. Immunol.</i> 160:5898-5906										
185.	Yi et al., "Cutting edge: Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA" (1998) <i>J. Immunol.</i> 161:4493-4497										
186.	Zhao et al., "Effect of different chemically modified oligodeoxynucleotides on immune stimulation" (1996) <i>Biochem. Pharmacol.</i> 51:173-182										
NMM	187.	Zon, Gerald, "Oligonucleoside phosphorothioates" Protocols for Oligonucleotides and Analogs, Chapter 8 in <i>Methods in Molecular Biology</i> , Volume 20 (1993) pp. 165-189									
EXAMINER: /N. M. Minnifield/ (03/05/2007)		DATE CONSIDERED: 03/05/2007									
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.											

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE